162 results on '"Senitzer, David"'
Search Results
2. Significance of Ethnicity in the Risk of Acute Graft-versus-Host Disease and Leukemia Relapse after Unrelated Donor Hematopoietic Stem Cell Transplantation
3. Hematopoietic Cell Transplantation with Cord Blood for Cure of HIV Infections
4. Expression of Activating KIR2DS2 and KIR2DS4 Genes after Hematopoietic Cell Transplantation: Relevance to Cytomegalovirus Infection
5. One-Antigen Mismatched Related versus HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Adults with Acute Leukemia: Center for International Blood and Marrow Transplant Research Results in the Era of Molecular HLA Typing
6. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens
7. Rapid, Flow Cytometric Assay for NK Alloreactivity Reveals Exceptions to Rules Governing Alloreactivity
8. Reduced-Intensity Conditioning followed by Peripheral Blood Stem Cell Transplantation for Adult Patients with High-Risk Acute Lymphoblastic Leukemia
9. The Effect of Single and Combined Activating Killer Immunoglobulin-like Receptor Genotypes on Cytomegalovirus Infection and Immunity after Hematopoietic Cell Transplantation
10. Impact of Graft Cell Dose on Transplant Outcomes following Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation: Higher CD34 + Cell Doses Are Associated with Decreased Relapse Rates
11. Detrimental Effect of Natural Killer Cell Alloreactivity in T-replete Hematopoietic Cell Transplantation (HCT) for Leukemia Patients
12. Identification of new MHC-restriction elements for presentation of the p210BCR-ABL fusion region to human cytotoxic T lymphocytes
13. [8] Role for Killer Immunoglobulin-like Receptors and/or their Ligands in Hematopoietic Stem Cell Transplantation (HCT).
14. Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status
15. Impact of CYP3A5/CYP2C19 Pharmacogenetics on Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Using Tacrolimus/Sirolimus (Tac/Sir) as Graft Versus Host Disease (GVHD) Prophylaxis
16. Severe Symptomatic Primary Human Cytomegalovirus Infection despite Effective Innate and Adaptive Immune Responses
17. New insights on the natural killer cell repertoire from a thorough analysis of cord blood cells
18. Tacrolimus/Sirolimus (T/S)-Based GvHD Prophylaxis Does Not Overcome Poor Outcome of HLA Mismatch after Unrelated Donor (URD) Peripheral Blood Stem Cell Transplantation
19. Impact of Donor Activating KIR2DS5 and KIR2DS2 on Outcome of Allogeneic Hematopoietic Cell Transplantation (AlloHCT) in Patients with Acute Myeloid Leukemia (AML)
20. Deleterious Effect of High-Expression HLA-DPB1 Allele Mismatch in Patients (pts) Undergoing 10/10 Match Unrelated Donor (MUD) Hematopoietic Cell Transplant (HCT) for Hematological Malignancies
21. Protein A-binding immunosuppressive mouse serum factors
22. Expression of Activating KIR2DS2 and KIR2DS4 genes following hematopoietic cell transplant (HCT): relevance to cytomegalovirus (CMV) infection
23. The role of KIR gene content and HLA-C group in susceptibility to HTLV-1-associated myelopathy / tropical spastic paraparesis in Peru
24. Drug Metabolism Gene Polymorphisms Influence Tacrolimus/Sirolimus Blood Levels and Incidence of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
25. Reduced Relapse Risk in Acute Myelogenous Leukemia (AML) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in Patients Who Experienced CMV Reactivation: Influence of Donor KIR Genotypes
26. 71 - Impact of CYP3A5/CYP2C19 Pharmacogenetics on Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Using Tacrolimus/Sirolimus (Tac/Sir) as Graft Versus Host Disease (GVHD) Prophylaxis
27. Analysis of graft survival in a trial of stem cell transplant in ALS
28. KIR Haplotype Assigment By Next Generation Sequencing
29. Protective effect of the KIR2DS1 gene in atopic dermatitis
30. Influence of Drug Absorption, Distribution, Metabolism, and Excretion (ADME) Variants on Sirolimus Blood Levels in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation
31. Phase I Trial of Escalated Doses of Targeted Marrow Radiation Delivered by Tomotherapy Combined with Etoposide and Cyclophosphamide; An Allogeneic HCT Preparative Regimen for Patients with Advanced Leukemia
32. Genetic Susceptibility to Anthracycline-Related Congestive Heart Failure (CHF) in Survivors of Hematopoietic Cell Transplantation (HCT)
33. Killer Immunoglobulin-like Receptor (KIR) and HLA Genotypes Affect the Outcome of Allogeneic Kidney Transplantation
34. Detection and Characterization of Antigen-Driven CD8+ T Lymphocytes Specific for Wilms' Tumor Antigen in Patients with Non-Hodgkin Lymphoma
35. Does the KIR2DS5 Gene Protect from Some Human Diseases?
36. Improved Outcome After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RI-HCT) for Myelodysplastic Syndrome (MDS) Using Tacrolimus/Sirolimus-Based Gvhd Prophylaxis.
37. Thrombotic Microangiopathy with Tacrolimus/Sirolimus-Based GVHD Prophylaxis Regimen in Patients Undergoing Hematopoietic Stem Cell Transplant from a Matched Unrelated Donor
38. Impact of Graft Cell Dose on Transplant Outcomes following Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation: Higher CD34+ Cell Doses Are Associated with Decreased Relapse Rates
39. Chemokine Receptor Gene Polymorphisms and Severity of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation from Sibling Donors.
40. The Use of Sirolimus Combined with Tacrolimus and Low-Dose Methotrexate Is Effective in Preventing Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation.
41. Tacrolimus and Sirolimus as GVHD Prophylaxis for HLA-MRD Allogeneic HCT Conditioned with 3 Regimens: Toxicity and Efficacy in 70 Patients.
42. Evidence of Donor-Derived Hematologic Malignancies after Hematopoietic Stem Cell Transplantation
43. Transplant CD34+ Cell Dose Affects Outcomes Following Allogeneic Peripheral Blood Stem Cell Transplantation from a Matched Unrelated Donor.
44. Evidence of Donor Derived Malignancies Following Hematopoietic Stem Cell Transplantation.
45. Identification of new MHC-restriction elements for presentation of the p210BCR-ABL fusion region to human cytotoxic T lymphocytes.
46. Autoimmune Mechanisms in the Pathogenesis of Rheumatic Fever.
47. Inhibition of Neutrophil Shape Change by an Inhibitor of Chemotaxis
48. EFFECTIVE TREATMENT OF FAMILIAL ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS
49. Spontaneous and induced cell-mediated reactivity to syngeneic cells
50. Favorable Impact of Allogeneic Stem Cell Transplantation in Patients with Therapy-Related Myelodysplasia Regardless of TP53 Mutational Status
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.